Nurix to present phase 1 data for BTK Degrader Bexobrutideg in CLL and Waldenström Macroglobulinemia at EHA 2025 and ICML
Nurix Therapeutics, Inc. announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia… read more.
